Arena Pharma (ARNA) Misses Q2 EPS by 1c

Arena Pharma (NASDAQ: ARNA) reported Q2 EPS of ($0.11), $0.01 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $9.5 million versus the consensus estimate of $10.44 million.

2016 Corporate Guidance Update

• R&D expenses between $78 to $84 million, including non-cash expenses of approximately $9 million
• G&A expenses between $27 to $33 million, including non-cash expenses of approximately $7 million
• The Company believes the costs reductions and strategic shift in priorities will allow it to manage its cash through completion of Phase 2 clinical trials for its three internal clinical stage programs.

For earnings history and earnings-related data on Arena Pharma (ARNA) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• Hesai Group (HSAI) Tops Q1 EPS by 8c